Evidence map›Paper›PMID 24553924›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2014

Changes in cerebral CB1 receptor availability after acute and chronic alcohol abuse and monitored abstinence.

Jenny Ceccarini, Titia Hompes, Anne Verhaeghen, Cindy Casteels, Hendrik Peuskens, Guy Bormans, Stephan Claes, Koen Van Laere

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 4 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 4 syntheses or guidelines pooled it, 115 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder.European psychiatry : the journal of the Association of European Psychiatrists · 2023
    Article
  17. Article
  18. Review
  19. Combinatorial approaches for treating neuropsychiatric social impairment.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Review
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Jenny CeccariniDivision of Nuclear Medicine, University Hospitals Leuven and Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium, MoSAIC, Molecular Small Animal Imaging Center, KU Leuven, 3000 Leuven, Belgium, Division of Psychiatry, University Hospital and KU Leuven, 3000 Leuven, Belgium, University Psychiatric Center, KU Leuven, 3070 Kortenberg, Belgium, Kliniek Broeders Alexianen, 3300 Tienen, Belgium, Laboratory for Radiopharmacy and Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium, and LIND, Leuven Institute for Neurobiology and Disease, KU Leuven, 3000 Leuven, Belgium.
Titia Hompes
Anne Verhaeghen
Cindy Casteels
Hendrik Peuskens
Guy Bormans
Stephan Claes
Koen Van Laere
KU Leuven · BEAlexian Brothers Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Involvement of the type 1 cannabinoid receptor (CB1R) in the effects of alcohol on the brain is supported by animal experiments, but how in vivo CB1R levels are altered in alcoholic patients is still unclear. To assess the short-time effects of a binge drinking episode on CB1R availability, 20 healthy social drinkers underwent [(18)F]MK-9470-positron emission tomography (PET) at baseline and after intravenous ethanol administration (ALC ACU). Moreover, 26 alcoholic patients underwent sequential CB1R PET after chronic heavy drinking (ALC CHR) and after 1 month of abstinence (ALC ABST). Seventeen healthy subjects served as controls. Compared with baseline, ALC ACU resulted in a global increase of CB1R availability (+15.8%). In contrast, a global decreased CB1R availability was found in ALC CHR patients (-16.1%) compared with controls, which remained unaltered after abstinence (-17.0%). Voxel-based analysis showed that ALC CHR patients had reduced CB1R availability, especially in the cerebellum and parieto-occipital cortex. After abstinence, reduced CB1R availability extended also to other areas such as the ventral striatum and mesotemporal lobe. In conclusion, whereas the acute alcohol effect is an increase in CB1R availability, chronic heavy drinking leads to reduced CB1R availability that is not reversible after 1 month of abstinence. Longer follow-up is required to differentiate whether this is a compensatory effect of repeated endocannabinoid overstimulation or an enduring trait-like feature. An enhanced CB1R signaling may offer a new therapeutic direction for treatment of the negative affective state produced by alcohol withdrawal and abstinence, which is critical for the maintenance of alcohol addiction.

Indexed as

Acute DiseaseAdultAlcohol DrinkingAlcoholismBinge DrinkingBrain MappingChronic DiseaseCohort StudiesDiagnostic and Statistical Manual of Mental DisordersHumansImage Processing, Computer-AssistedMaleMiddle AgedPositron-Emission TomographyPyridinesRadiopharmaceuticalsMK-9470PyridinesRadiopharmaceuticalsReceptor, Cannabinoid, CB1abstinenceacute alcohol effectalcoholismcannabinoid CB1 receptorchronic alcohol effectPET

Identifiers

PMID24553924
PMCPMC6608522
OpenAlexW2057475206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.